Januvia is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP -4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP -4), that results in an increased amount of active incretins (GLP -1 and GIP ), reduced amount of release of glucagon (diminishes its release) and increased release of insulin.
Januvia is an orally-active member of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. The benefit of this medicine is expected to be its lower side-effects of hypoglycemia in the control of blood glucose values. The drug works to diminish the effects of a protein/enzyme (by the inhibition of this protein/enzyme) on the pancreas at the level of release of glucagon (diminishes its release) and at the level of insulin (increases its synthesis and release) until blood glucose levels are restored toward normal, in which case the protein/enzyme-enzyme inhibitor becomes less effective and the amounts of insulin released diminishes thus diminishing the “overshoot” of hypoglycemia seen in other oral hypoglycemic agents.